Institute for Clinical Research Official Portal

BCX10013

Phase 1 Study: Dose Escalation of BCX10013 in Subjects with Paroxysmal Nocturnal Hemoglobinuria

An Open-Label, Multicenter, Intra-Subject Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Study No: BCX10013

Study Overview: This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with paroxysmal nocturnal hemoglobinuria (PNH). Approximately 15 participants will be enrolled in this study. Participants may receive treatment for up to 24 weeks.

Condition/Disease: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Intervention / Treatment: BCX10013 (Drug)

Study Start: 24-10-2023

Enrollment: Ongoing

Study Phase: Phase 1

Investigator site:

CCT FIH PNH - Investigator

Sponsor: BioCryst Pharmaceuticals 

ICR
National Institutes of Health (NIH)
Ministry of Health Malaysia
Institute For Clinical Research
Block B4, National Institutes of Health (NIH)
No.1, Jalan Setia Murni U13/52, Seksyen U13
40170 Shah Alam, Selangor Darul Ehsan
Malaysia
 
Phone: 603-3362 7700
Email: contact@crc.gov.my
 

NIH Official Portal

Client 1

Follow us on